US regulators have issued a speedy green light for the first and only drug able to treat chemotherapy overdose or severe allergic reactions.
News
Landmark NICE recommendation for AZ’ Lynparza
NICE has published final draft guidelines now supporting the use of AstraZeneca’s Lynparza on the NHS in England and Wales, marking the first time a cancer drug targeting an inherited genetic fault will be made available on the health service.
NICE welcomes Astellas’ Xtandi but rejects Janssen’s Zytiga
There was mixed news for prostate cancer patients in England and Wales this week after cost regulators for the NHS published preliminary guidelines supporting the use of Astellas’ Xtandi but rejecting Janssen’s Zytiga.
Novo Nordisk teams up with IBM for diabetes research
Novo Nordisk has announced that it will team up with IBM to use the firm’s Watson computing system in diabetes research.
Patient satisfaction with NHS hospitals shows ‘modest’ improvement
Patient satisfaction in NHS hospitals has improved over a nine-year period but only marginally, according to a longitudinal analysis of inpatient survey data.
UCL, Syncona create new gene therapy biopharma
UCL Business, the wholly-owned technology transfer company of UCL, has teamed up with investment group Syncona to create a new biopharmaceutical company called Freeline Therapeutics, which will focus on development and commercialisation of gene therapies for bleeding and other debilitating disorders.
EMA head outlines five-year plan
The EMA is ready to address the challenges ahead, according to the agency’s incoming executive director Professor Guido Rasi, who has outlined his vision for the next five years.
Last chance to enter International Clinical Researcher of the Year
The deadline for entry essays is the 8 January 2016, so don’t delay!
Limited time left to enter!
You’ve only got until 28 January to submit your essay for the Clinical Researcher of the Year – The Americas 2016 competition, and with Christmas approaching, time is definitely limited.
NHS England to tackle rising cost of GP indemnity
NHS England has announced plans to help GPs cope with extra demand over the winter period by reimbursing the indemnity costs for out-of-hours sessions.
Sanofi gets first dengue vaccine approval in Mexico
Sanofi’s dengue vaccine Dengavaxia has been approved in Mexico, making it the first vaccine for the disease to be licensed in the world.
Pfizer’s Xalkori gets speedy review for ROS1 NSCLC
The US Food and Drug Administration is undertaking a speedy review of Pfizer’s kinase inhibitor Xalkori for the treatment of patients with metastatic non-small cell lung cancer whose tumours are ROS1-positive.
Time spent in good health increasing, says new study
Increases in UK life expectancy are being accompanied by a rise in the proportion of life spent in good health, according to a new study.
US nods for Baxalta’s Vonvendi, Teva/Eagle’s Bendeka
US regulators have approved Baxalta’s Vonvendi, giving patients with Von Willebrand Disease access to the first recombinant treatment for their condition.
FDA clears Alexion’s enzyme replacement therapy Kanuma
US regulators have issued a green light for Alexion’s long-term enzyme replacement therapy Kanuma, giving patients with the ultra rare genetic disorder lysosomal acid lipase deficiency access to a targeted treatment for the first time.
